Tags

Type your tag names separated by a space and hit enter

Nabilone: an effective antiemetic in patients receiving cancer chemotherapy.

Abstract

Eighty evaluable patients receiving chemotherapy were entered on a random prospective double-blind study to evaluate the effectiveness of nabilone, a synthetic cannabinoid, compared to prochlorperazine. Most of these patients received cisplatin, a drug that universally produces severe nausea and vomiting, as part of a combination chemotherapy regimen. The patients served as their own controls, receiving either nabilone or prochlorperazine during two consecutive treatment courses with the identical chemotherapy. Side effects consisting of hypotension and lethargy were more pronounced with nabilone. Toxicity, in general, did not preclude antiemetic treatment and in no way interfered with chemotherapy. Sixty patients (75 per cent) reported nabilone to be more effective than prochlorperazine for relief of nausea and vomiting. Of these 60 patients, 46 required further chemotherapy and continued taking nabilone as the antiemetic of choice.

Links

  • Publisher Full Text
  • Authors

    , , ,

    Source

    MeSH

    Adolescent
    Adult
    Aged
    Antiemetics
    Antineoplastic Agents
    Clinical Trials as Topic
    Double-Blind Method
    Dronabinol
    Female
    Humans
    Male
    Middle Aged
    Nausea
    Prochlorperazine
    Vomiting

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    6271844

    Citation

    Einhorn, L H., et al. "Nabilone: an Effective Antiemetic in Patients Receiving Cancer Chemotherapy." Journal of Clinical Pharmacology, vol. 21, no. S1, 1981, 64S-69S.
    Einhorn LH, Nagy C, Furnas B, et al. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981;21(S1):64S-69S.
    Einhorn, L. H., Nagy, C., Furnas, B., & Williams, S. D. (1981). Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. Journal of Clinical Pharmacology, 21(S1), 64S-69S.
    Einhorn LH, et al. Nabilone: an Effective Antiemetic in Patients Receiving Cancer Chemotherapy. J Clin Pharmacol. 1981;21(S1):64S-69S. PubMed PMID: 6271844.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. AU - Einhorn,L H, AU - Nagy,C, AU - Furnas,B, AU - Williams,S D, PY - 1981/8/1/pubmed PY - 1981/8/1/medline PY - 1981/8/1/entrez SP - 64S EP - 69S JF - Journal of clinical pharmacology JO - J Clin Pharmacol VL - 21 IS - S1 N2 - Eighty evaluable patients receiving chemotherapy were entered on a random prospective double-blind study to evaluate the effectiveness of nabilone, a synthetic cannabinoid, compared to prochlorperazine. Most of these patients received cisplatin, a drug that universally produces severe nausea and vomiting, as part of a combination chemotherapy regimen. The patients served as their own controls, receiving either nabilone or prochlorperazine during two consecutive treatment courses with the identical chemotherapy. Side effects consisting of hypotension and lethargy were more pronounced with nabilone. Toxicity, in general, did not preclude antiemetic treatment and in no way interfered with chemotherapy. Sixty patients (75 per cent) reported nabilone to be more effective than prochlorperazine for relief of nausea and vomiting. Of these 60 patients, 46 required further chemotherapy and continued taking nabilone as the antiemetic of choice. SN - 0091-2700 UR - https://www.unboundmedicine.com/medline/citation/6271844/Nabilone:_an_effective_antiemetic_in_patients_receiving_cancer_chemotherapy_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0091-2700&date=1981&volume=21&spage=64S DB - PRIME DP - Unbound Medicine ER -